Temozolomide (TMZ) and cisplatin (CDDP) combination in naive patients with stage IV melanoma. Definitive results of a phase II multicenter trial

被引：0
|
作者：
Tourani, J.
Wiersbicka, E.
Mourey, L.
Guillot, B.
Sassolas, B.
Bedane, C.
机构：
[1] CHU Poitiers, Poitiers, France
[2] Inst Claudius Regaud, Toulouse, France
[3] CHU Montpellier, Hop St Eloi, Montpellier, France
[4] CHU Brest, Brest, France
[5] CHU Limoges, Limoges, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8572
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Final results of a phase II immunotherapy trial for stage III and IV melanoma patients.
    Riker, Adam Irwin
    Rossi, Gabriela R.
    Alsfeld, Leonard C.
    Denham, Fiona
    Tennant, Lucinda
    Ramsey, William Jay
    Link, Charles J.
    Harrison, Marilynn
    Vahanian, Nicholas N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group
    Gogas, H.
    Polyzos, A.
    Stavrinidis, I.
    Frangia, K.
    Tsoutsos, D.
    Panagiotou, P.
    Markopoulos, C.
    Papadopoulos, O.
    Pectasides, D.
    Mantzourani, M.
    Middleton, M.
    Vaiopoulos, G.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2006, 17 (12) : 1835 - 1841
  • [23] Combination of pembrolizumab (PEMBRO) plus temozolomide (TMZ) therapy in Chinese patients (pts) with advanced acral and mucosal melanoma.
    Hu, Tu
    Sun, Wei
    Xu, Yu
    Luo, Zhiguo
    Chen, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Definitive results of a phase II trial of cisplatin epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma
    Reni, M
    Passoni, P
    Panucci, MG
    Nicoletti, R
    Galli, L
    Balzano, G
    Zerbi, A
    Di Carlo, V
    Villa, E
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2679 - 2686
  • [25] Phase II study of temozolomide (TMZ) and pegylated interferon α-2b (PGI) in the treatment of advanced melanoma.
    Krown, SE
    Hwu, WJ
    Menell, JH
    Panageas, KS
    Lamb, LA
    Aird, S
    Williams, LJ
    Chapman, PB
    Livingston, PO
    Wolchok, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 718S - 718S
  • [26] Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study
    Chiarion-Sileni, V.
    Guida, M.
    Ridolfi, R.
    Romanini, A.
    Brugnara, S.
    Del Bianco, P.
    Perfetti, E.
    Cavallo, R.
    Pigozzo, J.
    Donati, D.
    De Salvo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Phase II trial of 4-hourly temozolomide (TMZ) in advanced malignant melanoma (MM)
    Arance, A
    Middleton, M
    Thatcher, N
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S371 - S371
  • [28] Temozolomide and cisplatin (TP) vs temozolomide (T) in patients with advanced melanoma. A randomized phase II of the Hellenic Cooperative Oncology Group.
    Bafaloukos, D
    Tsoutsos, D
    Kalofonos, HP
    Dimopoulos, AM
    Briassoulis, E
    Fountzilas, G
    Polyzos, A
    Skarlos, DV
    Georgoulias, V
    Gogas, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 721S - 721S
  • [29] Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.
    Si, L.
    Han, M.
    Chi, Z. H.
    Cui, C. L.
    Sheng, X. N.
    Li, S. M.
    Kong, Y.
    Guo, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study
    Christodoulou, C
    Bafaloukos, D
    Linardou, H
    Aravantinos, G
    Bamias, A
    Carina, M
    Klouvas, G
    Skarlos, D
    JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (01) : 61 - 65
12345